Another potent and soluble Hsp90 inhibitor used in preclinical studies that involve Hsp90 as a therapeutic target for cancer treatment is the semi-synthetic GA derivative 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) that binds to Hsp90 and inhibits its function but has the advantage to be water soluble and has a good bioavailability [28]. This evidence concerns the gene HSP90AB1 and cancer.